Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.
Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.
Rhea-AI Summary
Genentech, a member of the Roche Group, has received FDA approval for Xolair to reduce allergic reactions in patients with IgE-mediated food allergy. The approval is based on positive data from the NIH-sponsored Phase III OUtMATCH study, showing improved tolerance to food allergens in patients as young as 1 year old.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
-
Rhea-AI Summary
Roche (RHHBY) partners with PathAI to develop AI digital pathology algorithms for companion diagnostics, aiming to advance precision medicine. The collaboration will enhance patient access to targeted treatments by integrating AI-interpretation into pathology labs globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
-
Rhea-AI Summary
Genentech, a member of the Roche Group, announced new 72-week data from two global Phase III studies evaluating Vabysmo in macular edema due to branch and central retinal vein occlusion. The data showed that nearly 60% of people receiving Vabysmo were able to extend their treatment intervals to three or four months apart. Patients maintained vision gains and retinal drying for more than one year. Vabysmo is approved in the U.S. and more than 90 countries for people with wet AMD and DME.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
Rhea-AI Summary
Roche announces positive 72-week data from global Phase III studies evaluating Vabysmo in macular edema due to retinal vein occlusion. Up to 60% of patients were able to extend treatment intervals to three or four months apart. The drug maintained vision gains and retinal drying for more than a year, with well-tolerated safety profiles. Vabysmo is the first and only bispecific antibody approved for the eye, targeting angiopoietin-2 and vascular endothelial growth factor-A. It is approved in the US for RVO and in over 90 countries for nAMD and DME.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary
Roche Group achieved a 1% growth in group sales at constant exchange rates, with a 7% decline in Swiss Franc. The Pharmaceuticals Division sales increased by 6%, and the Diagnostics Division sales were 13% lower. The company's net income increased by 7% to CHF 12.4 billion, and core earnings per share increased by 6% to CHF 18.57. The company expects an increase in Group sales in the mid-single-digit range for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary
Genentech, a member of the Roche Group, announced positive 72-week data from two global Phase III studies evaluating Vabysmo in macular edema due to branch and central retinal vein occlusion. The results showed nearly 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart. Patients maintained vision gains and retinal drying for more than one year, with Vabysmo being well tolerated. Vabysmo is the first and only bispecific antibody approved for the eye and is approved in more than 90 countries. The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
Rhea-AI Summary
Roche announced that the European Commission has granted marketing authorization for Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy for subcutaneous injection. The new injection reduces treatment time by approximately 80% compared to standard IV infusion, with most injections taking between four and eight minutes. The approval is based on pivotal data from the Phase IB/III IMscin001 study, showing comparable levels of Tecentriq in the blood when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
-
Rhea-AI Summary
Remix Therapeutics (Remix) (SIX: RO, ROG; OTCQX: RHHBY) has announced a collaboration and license agreement with Roche for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform. Remix will receive an upfront payment of $30 million and is eligible to receive up to $12 million in near-term milestone payments, as well as preclinical, clinical, commercial and sales milestones of up to $1 billion and tiered royalties. Roche will have exclusive rights to specific targets, and Remix will conduct discovery and preclinical activities with Roche, while Roche will be responsible for development and commercialization of any resulting products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to acquire select parts of LumiraDx group (NASDAQ GS: LMDX) for a purchase price of USD 295 million, with an additional payment of up to USD 55 million. The acquisition will complement Roche’s centralised diagnostics portfolio across various disease areas, offering more affordable and accessible testing to patients worldwide. The transaction is expected to be finalized by mid-2024, subject to certain conditions including antitrust and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. FDA has accepted the company’s sBLA for Xolair for the reduction of allergic reactions from food exposure. The drug showed positive interim analysis results from the phase III OUtMATCH study, significantly increasing the amount of peanut, milk, egg, and cashew it took to cause an allergic reaction. The FDA is expected to make a decision on approval in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
FAQ
What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?
The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35.44 as of November 22, 2024.
What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?
The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 230.4B.
What is Roche Holdings Ltd. S/ADR (RHHBY) known for?
Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.
What is the significance of Columvi® (glofitamab) in Roche's portfolio?
Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
How does Roche contribute to personalized healthcare?
Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.
What recent innovation has Roche introduced in digital pathology?
Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.
What is Roche's approach to advancing haematology treatments?
Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.
ROCHE HOLDING LTD S/ADR